Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
54 participants
INTERVENTIONAL
2014-10-31
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis: While receiving treatment with Calmer, infants will show lower behavioral pain scores and lower heart rates, and more stable autonomic regulation as measured by heart rate variability indices, than infants given a soother plus facilitated tucking (standard of care) during routine blood collection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravenous and Topical Analgesics for Procedural Pain in Neonates
NCT00213200
Parent/Nurse Controlled Analgesia in the Neonatal Intensive Care Unit
NCT01823497
Assessment of Pain in Newborns and Older Infants (Infant Pain Assessment Study =
NCT03330496
Development of a Morphine Pharmacokinetic and Pharmacodynamic Model for the Neonatal Population
NCT03035578
Study of Morphine in Postoperative Infants to Allow Normal Ventilation
NCT00004696
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Calmer
This therapeutic platform, called the Calmer interacts with the infant to help reduce stress to help promote better outcomes. It is being tested to see if it mimics Kangaroo care, maternal skin to skin, to help promote better health outcomes. Infants would be placed on it prior, during and after bloodwork to see if it elicits a favorable response.
The Calmer
This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
Standard Care
Standard of care during bloodwork is receiving a soother and facilitated tucking.
Standard of Care
Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The Calmer
This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
Standard of Care
Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Preterm infants born at 27 to 36+6 completed weeks gestational age (GA) will be included
* GA is determined on the basis of the first day of the last menstrual period, early gestation ultrasonogram (in most cases) or best estimate based on neonatal examination
* Mothers must speak enough English to provide consent
Exclusion Criteria
* Infants who have received pharmacological analgesics or sedatives within 72 hours of the assessment
* History of maternal abuse of controlled drugs and substances; blood collection that occurs beyond the 35th completed week (35 weeks + 6 days) GA
* Small for GA defined as a birth weight at least 2 standard deviations below mean for GA
* Higher order multiples (e.g. triplets)
* Infants in a cot
27 Weeks
36 Weeks
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's & Women's Health Centre of British Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liisa Holsti
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liisa Holsti, PhD
Role: PRINCIPAL_INVESTIGATOR
Developmental Neurosciences and Child Health, Child and Family Research Institute and Dept. of Occupational Science and Occupational Therapy, UBC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BC Children's and Women's Health Centre
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CALMERP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.